Be part of the knowledge.™

Neurology and Neurosurgery

10381

LikeLikedUnlike

OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
- Mike Sharma, MD, MSc, FRCPC
  Peer
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
- Ashkan Shoamanesh, MD
  Peer
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
On the Frontlines of Schizophrenia
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
- Alexandria May, PharmD, BCPS
  Peer
- Apurva Bhatt, MD
  Peer
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
NeuroFrontiers
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
Iron Deposition and Cognitive Fatigue in Multiple Sclerosis
NeuroFrontiers
Iron Deposition and Cognitive Fatigue in Multiple Sclerosis
Evaluating Structured Interventions for Cognitive Support in MS
AudioAbstracts
Evaluating Structured Interventions for Cognitive Support in MS
- Hallie Blevins, PhD
  Peer
advertisement

Q-Challenge™
Cases in Multiple Sclerosis
3 questions
advertisement

Tau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers
Medical Industry Feature
Tau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers
- Yuval Zabar, MD
  Peer
- Michelle Mielke, PhD
  Peer
- Henrik Zetterberg, MD, PhD
  Peer
Treating Mild Cognitive Impairment in Alzheimer’s Disease: A Therapy’s 2-Way MOA
Medical Industry Feature
Treating Mild Cognitive Impairment in Alzheimer’s Disease: A Therapy’s 2-Way MOA
Amyloid and Tau in Alzheimer’s Disease: Insights into Disease Progression
Medical Industry Feature
Amyloid and Tau in Alzheimer’s Disease: Insights into Disease Progression
- Holly M. Brothers, PhD
  Peer
- Niklas Mattsson-Carlgren, MD, PhD
  Peer
New Trial Device Opens Blood-Brain Barrier to Treat Glioblastoma
Medical Industry Feature
New Trial Device Opens Blood-Brain Barrier to Treat Glioblastoma
- Brian Gill, M.D.
  Peer
Reassessing the Full Clinical Picture of ADHD
Medical Industry Feature
Reassessing the Full Clinical Picture of ADHD
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Ann Childress, MD
  Peer
MMN in Practice: A Rare Motor Neuropathy Often Misdiagnosed
Medical Industry Feature
MMN in Practice: A Rare Motor Neuropathy Often Misdiagnosed
- Jennifer Caudle, DO, FACOFP
  Peer
- Katie Beadon, MD, MASc, FRCPC
  Peer

Medical News
Neuronal IDOL deletion links LDLR/APOE regulation to reduced amyloid and synapt…
02/16/2026
Medical News
Preclinical Insights Into CD4+ CAR-T Targeting Amyloid Beta in Alzheimer's Dise…
02/13/2026
Medical News
New Findings on Visual Dysfunction in Parkinson's Disease
02/12/2026
Medical News
Understanding Parkinson’s Disease and the Brain’s Action Network
02/11/2026
Medical News
Speed-Focused Cognitive Training With Booster Sessions Linked to Lower Dementia…
02/10/2026
Medical News
EBV-Specific CD8+ T Cells in CSF: New Insights Into Early MS Immune Biology
02/09/2026

Program Chapters

Segment Chapters

Playlist:

Recommended